A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

Phase 2 Completed 111 enrolled Leap Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

Timeline

Start: 2018-03-05
Primary completion: 2020-09-09
Completion: 2021-01-27

Publications

Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecol Oncol. 2023 May;172:82-91. doi: 10.1016/j.ygyno.2023.03.013. Epub 2023 Mar 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DKN-01	Monoclonal antibody	300 mg	Intravenous
Subject	DKN-01	Monoclonal antibody	600 mg	Intravenous
Subject	Paclitaxel	Small molecule	—	Intravenous

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

Summary

Timeline

Publications

Drugs

Indications